Descripción del proyecto
Los investigadores ignoran el capitalismo en lo que respecta a tres de las enfermedades infecciosas más peligrosas
La crisis del ébola que se produjo entre el 2014 y el 2016 en África occidental hizo sonar la alarma sobre las grandes deficiencias en la preparación mundial contra epidemias graves y emergencias para la salud pública. La segunda lista de enfermedades prioritarias de 2018 de la Organización Mundial de la Salud identificó ocho enfermedades y patógenos con un potencial epidémico grave contra los que no había fármacos o vacunas eficaces. La enfermedad del virus del Ébola (EVD, por sus siglas en inglés) y la fiebre del Valle del Rift (FVR) están entre ellos. Se consideró la inclusión de la fiebre de chikungunya y se determinó que era un grave riesgo para la salud. Estas enfermedades se dan más en los países de ingresos medios y bajos, y no hay incentivos de mercado para el desarrollo de vacunas. La financiación europea del proyecto ECRC contribuye a que la Coalición para la Preparación e Innovación frente a Epidemias en Noruega acelere el desarrollo de vacunas para proteger la salud y el bienestar económico de millones.
Objetivo
The objective of this specific grant agreement (SGA) is to leverage co-funding from the European Commission to accelerate the development of vaccines against Rift Valley Fever (RVF), Chikungunya (CHIK) and Ebola virus diseases (EVD).
• RVF and CHIK vaccine development will be addressed by CEPI’s third Call for Proposals (CFP3), and it will structured through launching two sub-calls; CFP3i and CFP3ii. This SGA only relates to CFP3i, and has the following objectives:
a) For RVFV vaccines, to support clinical testing or activities enabling clinical Phase l/ll testing of the most advanced RVFV candidates, including identification of correlates of protection and their validation, which can facilitate future regulatory approval.
b) For CHIKV vaccines, to support the rapid progression of the most advanced clinical CHIKV vaccine candidates through mid-stage and late-stage clinical development, and to support activities enabling future efficacy testing, including identification of correlates of protection and their validation that can facilitate future regulatory approval.
The call will be launched January 2019 and will be open to all entities that meet the eligibility criteria and agree to CEPI’s award conditions – which are aligned with EU regulations.
EVD vaccine development will focus on addressing the remaining evidence gaps towards the licensure by FDA and/or EMA of the leading vaccine candidates, particularly on generating evidence of the protective efficacy of the vaccines in humans in the context of an outbreak. Towards this scope, and in order to take advantage of the research opportunities afforded by any large-scale Ebola outbreak, CEPI is expected to facilitate the rapid launch of clinical studies of the lead Ebola vaccine candidates. If feasible, the standard CfP mechanism will be used. However, in duly justified emergencies CEPI may award a grant without a call for proposals.
RVF and EVD are included among the WHO R&D Blueprint list of priority pathogens in 2018, while CHIKV was deemed to present a major public health risks for which “further research and development is needed” and “efforts in the interim to understand and mitigate them are encouraged”. Despite this stated urgency, action has been lacking – in part because low and middle-income countries are most at risk for future outbreaks and market incentives are lacking, both due to this and the inherently unpredictable nature and timing of future outbreaks. The current pipeline of candidates for these three pathogens does however bring a lot of promise; since there are quite a few mature candidates in the pipeline, targeted investments from CEPI and the EC could bring significant benefit and further strengthen and align the two entities’ existing priorities in vaccine development.
Ámbito científico
CORDIS clasifica los proyectos con EuroSciVoc, una taxonomía plurilingüe de ámbitos científicos, mediante un proceso semiautomático basado en técnicas de procesamiento del lenguaje natural.
CORDIS clasifica los proyectos con EuroSciVoc, una taxonomía plurilingüe de ámbitos científicos, mediante un proceso semiautomático basado en técnicas de procesamiento del lenguaje natural.
Palabras clave
Programa(s)
Convocatoria de propuestas
Consulte otros proyectos de esta convocatoriaConvocatoria de subcontratación
H2020-SGA-SC1-CEPI-2019
Régimen de financiación
CSA - Coordination and support actionCoordinador
0277 Oslo
Noruega